Add 2 More Reports For 20% off

Report Overview

2023

Base Year

2017-2023

Historical Year

2024-2032

Forecast Year

Global Central Nervous System Treatment Market Outlook

The global central nervous system treatment market is expected to grow at a CAGR of 8.1% during the period 2024-2032. The market is likely to be driven by development of new treatment systems, regulations seeking to support treatment systems for central nervous system disorders, and technological innovations. North America, Europe and Asia are expected to be key markets.

central nervous system treatment market

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Global Market Likely to be Driven by Increasing Incidence of Neurological Disorders

The nervous system comprises central nervous system (CNS) (consisting of the brain and the spinal cord) and the peripheral nervous system (consisting of nerves, including the autonomic nervous system, outside of the brain and spinal cord, including those in the arms, legs, and trunk of the body). Together, the brain and the spinal cord act as the main "processing centre" for the entire nervous system, and control all the functions of the body.

Several different medical conditions could affect the nervous system, including degenerative diseases (including Alzheimer’s disease and Parkinson’s disease), blood vessel disorders in the brain (including arteriovenous malformations and cerebral aneurysms), tumours (benign and malignant), disorders of the pituitary gland, demyelinating diseases (such as multiple sclerosis), headaches (including migraines), epilepsy, head injuries like concussions and brain trauma, movement disorders (such as tremors and Parkinson’s disease), neuro-ophthalmologic diseases (vision problems as a result from damage to the optic nerve or its connections to the brain), peripheral nerve diseases (neuropathy), spine disorders, mental disorders (such as schizophrenia), infections (such as meningitis), stroke, etc.

Regulatory Frameworks Looking to Facilitate Development of Personalized Medicine Expected to Drive Market Growth

Central nervous system disorders signify a key area of unmet medical need. Personalized medicine (PM) is a novel concept that seeks to capitalize on known variability in patients, which causes differences in disease susceptibility and response to medication. The European regulatory network seeks to facilitate the development of PM methods for central nervous system disorders, including biomarkers (BMs), companion diagnostics, pharmacogenomics, and rare diseases; new methodologies and innovative clinical trial designs; and advanced treatments and therapies (e.g. gene therapies, somatic cell therapies, and tissue-engineered medicines). Such developments are expected to drive the global central nervous system treatment market. Increased focus on patient centricity and participation of patient groups has led to enhanced regulatory backing, including devoted scientific advice resources, new guidance documents, and multistakeholder platforms to meet challenges in PM development. Such initiatives led to some success (e.g., BM qualification), and there is hope that these would facilitate future approval of personalized central nervous system medicines.

Availability of Treatment Systems and Medical Practitioners Expected to Contribute to Market Growth

Neuroradiology (a branch of neuroscience medicine) seeks to diagnose and treat nervous system problems. Treatments include balloon angioplasty and stenting of carotid or vertebral artery; intra-arterial therapy for stroke; radiation oncology of the brain and spine; endovascular embolization and coiling to treat cerebral aneurysms; kyphoplasty and vertebroplasty to treat vertebral fractures; needle biopsies, spine and soft tissues; etc. Treatment may also include medicines [possibly administered by a drug pump (like those used for people with severe muscle spasms)], deep brain stimulation, spinal cord stimulation, rehabilitation/physical therapy after brain injury or stroke, spinal surgery, etc. Availability of treatment systems, along with that of health care providers, is expected to boost the global central nervous system treatment market. Health care providers from multiple specialties may be required to treat central nervous system related conditions. These may include neurologist, vascular surgeon, neurosurgeon, neuropsychologist, pain physician, psychiatrist, psychologist, radiologist, neuroscientist, nurse practitioners (NPs), physician assistants (PAs), nutritionists or dietitians, primary care doctors, physical therapists, occupational therapists, speech-language therapists, etc.

Market Segmentation

central nervous system treatment market by segments

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

By type, the market is segmented into:

  • Neurovascular Diseases (further broken down by type as given below)
    • Hemorrhagic Stroke
    • Ischemic Stroke
    • Others
  • Neurodegenerative Diseases (further broken down by type as given below)
    • Alzheimer’s Disease
    • Parkinson’s Disease
    • Multiple Sclerosis
    • Others
  • Mental Health (further broken down by type as given below)
    • Epilepsy 
    • Mood Disorders
    • Anxiety Disorders
    • Others
  • Infectious Diseases (further broken down by type as given below)
    • Meningitis 
    • Encephalitis 
    • Others
  • Others

By drug class, the market is divided into:

  • Immunomodulatory Drugs
  • Interferons
  • Decarboxylase Inhibitors
  • Dopamine Agonists
  • Antidepressants
  • Analgesics
  • Others

By drug type, the market is classified into:

  • Biologics
  • Non-Biologics

By region, the market is segmented into:

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa

central nervous system treatment market by region

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Key Industry Players in the Market

The report presents a detailed analysis of the following key players in the global central nervous system treatment market, looking into their capacity, and latest developments like capacity expansions, plant turnarounds, and mergers and acquisitions:

  • Teva Pharmaceutical Industries Ltd.
  • Pfizer, Inc.
  • F. Hoffmann-La Roche Ltd
  • Otsuka Pharmaceutical Co., Ltd.
  • Angelini S.p.a.
  • Others

The EMR report gives an in-depth insight into the industry by providing a SWOT analysis as well as an analysis of Porter’s Five Forces model.

Key Highlights of the Report

REPORT FEATURES DETAILS
Base Year 2023
Historical Period 2017-2023
Forecast Period 2024-2032
Scope of the Report

Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:

  • Disease Type
  • Drug Class
  • Drug Type
  • Region
Breakup by Disease Type
  • Neurovascular Diseases (further broken down by type as given below)
    • Hemorrhagic Stroke
    • Ischemic Stroke
    • Others
  • Neurodegenerative Diseases (further broken down by type as given below)
    • Alzheimer’s Disease
    • Parkinson’s Disease
    • Multiple Sclerosis
    • Others
  • Mental Health (further broken down by type as given below)
    • Epilepsy 
    • Mood Disorders
    • Anxiety Disorders
    • Others
  • Infectious Diseases (further broken down by type as given below)
    • Meningitis 
    • Encephalitis 
    • Others
  • Others
Breakup by Drug Class
  • Immunomodulatory Drugs
  • Interferons
  • Decarboxylase Inhibitors
  • Dopamine Agonists
  • Antidepressants
  • Analgesics
  • Others
Breakup by Drug Type
  • Biologics
  • Non-Biologics
Breakup by Region
  • North America
    • United States of America 
    • Canada
  • Europe
    • United Kingdom
    • Germany
    • France
    • Italy
    • Others
  • Asia Pacific
    • China
    • Japan
    • India
    • ASEAN
    • Australia
    • Others
  • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Others
  • Middle East and Africa
    • Saudi Arabia
    • United Arab Emirates
    • Nigeria
    • South Africa
    • Others
Market Dynamics
  • SWOT Analysis
  • Porter's Five Forces Analysis
  • Key Indicators for Demand
  • Key Indicators for Price
Competitive Landscape
  • Market Structure
  • Company Profiles
    • Company Overview
    • Product Portfolio
    • Demographic Reach and Achievements
    • Certifications
Companies Covered
  • Teva Pharmaceutical Industries Ltd.
  • Pfizer, Inc.
  • F. Hoffmann-La Roche Ltd
  • Otsuka Pharmaceutical Co., Ltd.
  • Angelini S.p.a.
  • Others
Report Price and Purchase Option Explore our purchase options that are best suited to your resources and industry needs.
Delivery Format Delivered as an attached PDF and Excel through email, with an option of receiving an editable PPT, according to the purchase option.

*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*

Looking for specific insights?

Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!

Key Questions Answered in the Report

The global central nervous system treatment market is projected to grow at a CAGR of 8.1% between 2024 and 2032.

The major drivers of the market include the increasing geriatric population, launch of new prospective products and pipeline drugs, favourable reimbursement policies, and improving healthcare infrastructure.

Increasing incidence of neurological disorders and regulations seeking to support treatment systems for central nervous system disorders are the key industry trends propelling the market's growth.

The major regions in the industry are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific.

The different types of central nervous system treatment in the market are neurovascular diseases, neurodegenerative diseases, mental health, and infectious diseases, among others.

Based on drug class, the market is divided into immunomodulatory drugs, interferons, decarboxylase inhibitors, dopamine agonists, antidepressants, and analgesics, among others.

The various drug types in the market are biologics and non-biologics.

The major players in the industry are Teva Pharmaceutical Industries Ltd., Pfizer, Inc., F. Hoffmann-La Roche Ltd, Otsuka Pharmaceutical Co., Ltd., and Angelini S.p.a., among others.

Purchase Full Report

Datasheet

 

USD 2,969

USD 2,699

tax inclusive*

  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

One User

USD 5,499

USD 4,999

tax inclusive*

  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Five User License

Five Users

USD 6,599

USD 5,999

tax inclusive*

  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

Unlimited Users

USD 7,699

USD 6,999

tax inclusive*

  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

How To Order

Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.

Select License Type

Choose the right license for your needs and access rights.

Click on ‘Buy Now’

Add the report to your cart with one click and proceed to register.

Select Mode of Payment

Choose a payment option for a secure checkout. You will be redirected accordingly.

Strategic Solutions for Informed Decision-Making

Connect For More Information

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.

Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.

We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.

We’re here to help answer any questions about our products and services.

Contact us

Our Offices


Australia

63 Fiona Drive, Tamworth, NSW

+61 448 06 17 27

India

C130 Sector 2 Noida, Uttar Pradesh 201301

+91-858-608-1494

Philippines

40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.

+63 287899028, +63 967 048 3306

United Kingdom

6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London

+44-753-713-2163

United States (Head Office)

30 North Gould Street, Sheridan, WY 82801

+1-415-325-5166

Vietnam

193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City

+84865399124

30 North Gould Street, Sheridan, WY 82801

+1-415-325-5166

63 Fiona Drive, Tamworth, NSW

+61 448 06 17 27

C130 Sector 2 Noida, Uttar Pradesh 201301

+91-858-608-1494

40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.

+63 287899028, +63 967 048 3306

6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London

+44-753-713-2163

193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City

+84865399124